These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1446358)

  • 1. Synthesis and crystal structure of optically active 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate (NZ-105).
    Sakoda R; Matsumoto H; Seto K
    Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2377-81. PubMed ID: 1446358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 1,4-dihydropyridine-5-phosphonates and their calcium-antagonistic and antihypertensive activities: novel calcium-antagonist 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) and its crystal structure.
    Sakoda R; Kamikawaji Y; Seto K
    Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2362-9. PubMed ID: 1446356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activities of optical isomers of 2-(4-diphenylmethyl-1-piperazinyl)ethyl 5-(4,6-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate dihydrochloride (NIP-101).
    Sakoda R; Kamikawaji Y; Seto K
    Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2370-6. PubMed ID: 1446357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms underlying the slow onset of action of a new dihydropyridine, NZ-105, on a cultured smooth muscle cell line.
    Tamura T; Saigusa A; Kokubun S
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Apr; 343(4):405-10. PubMed ID: 1649411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term oral administration of NZ-105, a novel calcium antagonist, with or without propranolol in spontaneously hypertensive rats.
    Shudo C; Masuda Y; Sakai T; Tanaka S; Shigenobu K; Kasuya Y
    J Pharm Pharmacol; 1993 Jun; 45(6):525-9. PubMed ID: 8103100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and pharmacological effects of optically active 2-[4-(4-benzhydryl-1-piperazinyl)phenyl]-ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate hydrochloride.
    Ashimori A; Uchida T; Ohtaki Y; Tanaka M; Ohe K; Fukaya C; Watanabe M; Kagitani M; Yokoyama K
    Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):108-11. PubMed ID: 2049794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and X-ray crystal structure of the calcium channel antagonist: dimethyl 1,4-dihydro-2,6-dimethyl-4-[4'-(4H-4-oxo-1-benzopyran-2-yl)phenyl]- 3,5-pyridine dicarboxylate.
    Tunçbilek M; Ozbey S; Kendi E; Yildirim E; Erol K; Ertan R
    Farmaco; 1999 Oct; 54(10):660-5. PubMed ID: 10575734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Affinity of Z-105 to the 1,4-dihydropyridine type calcium channel and several other receptor bindings in the central nervous system].
    Niwa M; Nozaki M; Kobayashi M; Tsurumi K
    Nihon Yakurigaku Zasshi; 1992 Jul; 100(1):59-66. PubMed ID: 1322857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits].
    Toyoda K; Kitahara M; Yamashita T; Shudo C; Masuda Y; Sakashita M; Tanaka S; Saito Y
    Nihon Yakurigaku Zasshi; 1994 May; 103(5):231-9. PubMed ID: 8188119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina.
    Saito T; Fujii K; Takizawa T; Toyosaki T; Kuwabara Y; Kobayashi S; Ichikawa H; Karaki A; Yamazaki Y; Iwata J; Yamada K; Tomiya H; Takeda K; Inagaki Y
    Arzneimittelforschung; 1996 Sep; 46(9):861-7. PubMed ID: 8876934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo- 1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3 -pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin.
    Niwa K; Yamada K; Furukawa T; Shudo N; Seto K; Matsumoto T; Takao S; Akiyama S; Shimazu H
    Cancer Res; 1992 Jul; 52(13):3655-60. PubMed ID: 1617639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activities of optical isomers of 2-(4-diphenylmethyl-1-piperazinyl)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate (manidipine) dihydrochloride.
    Kajino M; Wada Y; Nagai Y; Nagaoka A; Meguro K
    Chem Pharm Bull (Tokyo); 1989 Aug; 37(8):2225-8. PubMed ID: 2598325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive activity of 3-[4-(substituted amino)phenylalkyl]ester derivatives.
    Ashimori A; Ono T; Inoue Y; Morimoto S; Eda M; Uchida T; Ohtaki Y; Fujino Y; Kido H; Ogura Y
    Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):91-9. PubMed ID: 2049813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of efonidipine hydrochloride (NZ-105) on modification of low density lipoprotein induced by rat cultured endothelial cells].
    Ito S; Higashino R; Tanaka T; Takei M; Kurimoto T; Matsuda K
    Nihon Yakurigaku Zasshi; 1995 Oct; 106(4):263-70. PubMed ID: 8537073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and pharmacological activity of stereoisomers of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester.
    Muto K; Kuroda T; Kawato H; Karasawa A; Kubo K; Nakamizo N
    Arzneimittelforschung; 1988 Nov; 38(11A):1662-5. PubMed ID: 3219137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permanently charged chiral 1,4-dihydropyridines: molecular probes of L-type calcium channels. Synthesis and pharmacological characterization of methyl(omega-trimethylalkylammonium) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate iodide, calcium channel antagonists.
    Peri R; Padmanabhan S; Rutledge A; Singh S; Triggle DJ
    J Med Chem; 2000 Jul; 43(15):2906-14. PubMed ID: 10956198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antihypertensive activity of 1,4-dihydropyridine derivatives with a 4-(disubstituted phenyl) ring and an aminoalkyl ester group: highly potent and long-lasting calcium antagonists.
    Kanno H; Yamaguchi H; Okamiya Y; Sunakawa K; Takeshita T; Naruchi T
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2049-54. PubMed ID: 1423758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats.
    Shudo C; Masuda Y; Sugita H; Tamura T; Furukawa S; Hayashi K; Hirata H; Shikada K; Tanaka S; Tomita K
    Arzneimittelforschung; 1996 Sep; 46(9):852-4. PubMed ID: 8876932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor model for the molecular basis of tissue selectivity of 1, 4-dihydropyridine calcium channel drugs.
    Langs DA; Strong PD; Triggle DJ
    J Comput Aided Mol Des; 1990 Sep; 4(3):215-30. PubMed ID: 2177783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.
    Ramesh M; Matowe WC; Akula MR; Vo D; Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Knaus EE
    J Med Chem; 1998 Feb; 41(4):509-14. PubMed ID: 9484501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.